Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-02-24
2000-07-04
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514431, 514443, 514569, 514456, 514219, 514394, 514339, A61K 3138
Patent
active
060839732
ABSTRACT:
This invention provides methods of of inhibiting mucin production in a mammal comprising administering to the mammal an RAR antagonist. Preferably, the RAR antagonist is an RAR.alpha. selective antagonist.
In another aspect, this invention provides methods of inhibiting mucin gene expression in a human epithelial cell by contacting the cell with an RAR antagonist, preferably an RAR.alpha. selective antagonist.
REFERENCES:
patent: 5391766 (1995-02-01), Klaus et al.
patent: 5512683 (1996-04-01), Klaus et al.
Kagechika, et al., Biochem. and Biophy. Res. Communications, vol. 231, pp. 243-248 (1997) "Inhibition of IL-1-Induced IL-6 Production by Synthetic Retinoids".
Apfel, et al., Proc. Natl. Acad. Sci. USA, vol. 89, pp. 7129-7133 (Aug. 1992) "A retinoic acid receptor .varies. antagonist selectively counteracts retinoic acid effects".
Teng, et al., J. Med. Chem., vol. 40, pp. 2445-2451 (1997) "Identification of Highly Potent Retinoic Acid Receptor .varies.-Selective Antagonists".
Keidell, et al., The Journal of Biogical Chemistry, vol. 272:29, pp. 18267-18272 (1997) "Mutational Analysis Reveals That All-trans-retinoic, 9-cis-Retinoic acid, and Antagonist Interact with Distinct Binding Determinants of RAR.varies.".
Frank Chytil, American Journal Physiol.vol. 262 (Lung Cell. Mol. Physio. 6): pp. L517-527 (1992) "The lungs and vitamin A".
Wu, et al., Eur. Respir. Journal, vol. 10: pp. 2398-2403 (1997) "Growth and differentiation of conducting airway epithelial cells in culture".
Eyrolles, et al., Journal Med. Chem., vol. 37: pp. 1508-1517 (1994) "Retinobenzoic Acids. 6. Retinoid Antagonists with a Heterocyclic Ring".
Guzman, et al., Am. Journal Physiol., vol. 271 (Lung Cell. Mol. Physio. 15): pp. L1023-1028 (1996) "Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids".
Christensen, et al., Am. J. Respir. Cell Mol. Biol., vol. 9: pp. 287-294 (1993) "Quantitative Ultrastructural Analysis of the Relationship between Cell Growth, Shape Change, and Mucosecretory Differtiation in Cultered Hamster Tracheal Epithelial Cells Exposed to Retinoic Acid".
An, et al., Am. J. Respir. Cell Mol. Biol., vol. 10: pp. 546-551 (1994) "Expression of MUC2 Gene Is Down-regulated by Vitamin A at the Transcriptional Level In Vitro in Tracheobronchial Epithelial Cells".
Steiger, et al., Am. J. Respir. Cell Mol. Biol., vol. 12: pp. 307-314 (1995) "Concurrent Increases in the Storage and Release of Mucin-like Molecules by Rat Airway Epithelial Cells in Response to Bacterial Endotoxin".
Gray, et al., Am. J. Respir. Cell Mol. Biol., vol. 14: pp. 104-112 (1996) "Mucociliary Differentiation of Serially Passaged Normal Human Tracheobronchial Epithelial Cells".
Eckhardt, et al., Toxlet, vol. 70: pp. 299-308 (1994) "A retinoic acid receptor .varies. antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations in vivo".
Peries Rohan
Reamer James H.
Syntex (U.S.A.) Inc.
LandOfFree
Methods for inhibiting mucin secretion using RAR .alpha. selecti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting mucin secretion using RAR .alpha. selecti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting mucin secretion using RAR .alpha. selecti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486947